AAAAAA

   
Results: 1-8 |
Results: 8
POWER CORRELATION FOR EGSTAR AGITATOR
Authors: OHISHI T HIRAOKA S KATO Y TADA Y CHUN HG YAMAGUCHI T
Citation: T. Ohishi et al., POWER CORRELATION FOR EGSTAR AGITATOR, Kagaku kogaku ronbunshu, 24(6), 1998, pp. 907-911
TREATMENT OF REFRACTORY CHRONIC LYMPHOCYTIC-LEUKEMIA WITH FLUDARABINEPHOSPHATE VIA THE GROUP-C PROTOCOL MECHANISM OF THE NATIONAL-CANCER-INSTITUTE - 5-YEAR FOLLOW-UP REPORT
Authors: SORENSEN JM VENA DA FALLAVOLLITA A CHUN HG CHESON BD
Citation: Jm. Sorensen et al., TREATMENT OF REFRACTORY CHRONIC LYMPHOCYTIC-LEUKEMIA WITH FLUDARABINEPHOSPHATE VIA THE GROUP-C PROTOCOL MECHANISM OF THE NATIONAL-CANCER-INSTITUTE - 5-YEAR FOLLOW-UP REPORT, Journal of clinical oncology, 15(2), 1997, pp. 458-465
RELATIONSHIP BETWEEN RESPONSE RATE AND MEDIAN SURVIVAL IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG-CANCER - COMPARISON OF ONCONASE(R) WITHOTHER ANTICANCER AGENTS
Authors: MIKULSKI SM CHUN HG MITTELMAN A PANELLA T PUCCIO CA SHOGEN K COSTANZI JJ
Citation: Sm. Mikulski et al., RELATIONSHIP BETWEEN RESPONSE RATE AND MEDIAN SURVIVAL IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG-CANCER - COMPARISON OF ONCONASE(R) WITHOTHER ANTICANCER AGENTS, International journal of oncology, 6(4), 1995, pp. 889-897
PHASE-I TRIAL OF FLUDARABINE MONOPHOSPHATE (FAMP) PLUS ALPHA-INTERFERON (IFN-A) IN REFRACTORY LOW-GRADE NON-HODGKINS-LYMPHOMA (LGNHL)
Authors: CHUN HG AHMED T MITTELMAN A NELSON J FELDMAN E LERNER R
Citation: Hg. Chun et al., PHASE-I TRIAL OF FLUDARABINE MONOPHOSPHATE (FAMP) PLUS ALPHA-INTERFERON (IFN-A) IN REFRACTORY LOW-GRADE NON-HODGKINS-LYMPHOMA (LGNHL), Blood, 86(10), 1995, pp. 3227-3227
SIMULTANEOUS MEASUREMENT OF THE CELL-DIFFERENTIATING AGENT HEXAMETHYLENE BISACETAMIDE AND ITS METABOLITES BY GAS-CHROMATOGRAPHY
Authors: ROTH JS KELLEY JA CHUN HG WARD FT
Citation: Js. Roth et al., SIMULTANEOUS MEASUREMENT OF THE CELL-DIFFERENTIATING AGENT HEXAMETHYLENE BISACETAMIDE AND ITS METABOLITES BY GAS-CHROMATOGRAPHY, Journal of chromatography B. Biomedical applications, 652(2), 1994, pp. 149-159
INCIDENCE AND TREATMENT OF TUMOR LYSIS SYNDROME IN PATIENTS WITH ACUTE-LEUKEMIA
Authors: RAZIS E ARLIN ZA AHMED T FELDMAN EJ PUCCIO C COOK P CHUN HG HELSON L MITTELMAN A
Citation: E. Razis et al., INCIDENCE AND TREATMENT OF TUMOR LYSIS SYNDROME IN PATIENTS WITH ACUTE-LEUKEMIA, Acta haematologica, 91(4), 1994, pp. 171-174
CHLOROQUINOXALINE SULFONAMIDE - A SULFANILAMIDE ANTITUMOR AGENT ENTERING CLINICAL-TRIALS
Authors: FISHERMAN JS OSBORN BL CHUN HG PLOWMAN J SMITH AC CHRISTIAN MC ZAHARKO DS SHOEMAKER RH
Citation: Js. Fisherman et al., CHLOROQUINOXALINE SULFONAMIDE - A SULFANILAMIDE ANTITUMOR AGENT ENTERING CLINICAL-TRIALS, Investigational new drugs, 11(1), 1993, pp. 1-9
TUMOR LYSIS SYNDROME (TLS) IN PATIENTS RECEIVING FLUDARABINE (F) FOR CHRONIC LYMPHOCYTIC-LEUKEMIA (CLL)
Authors: FRAME JN SORENSEN JM QASHU N VENA D CHRISTIAN M CHUN HG CHESON BD
Citation: Jn. Frame et al., TUMOR LYSIS SYNDROME (TLS) IN PATIENTS RECEIVING FLUDARABINE (F) FOR CHRONIC LYMPHOCYTIC-LEUKEMIA (CLL), Blood, 82(10), 1993, pp. 10000139-10000139
Risultati: 1-8 |